Literature DB >> 29074819

Continued Search for Therapies to Favorably Modify Phosphate and FGF23 Levels in CKD.

Rupal Mehta1,2, Tamara Isakova3,2.   

Abstract

Entities:  

Keywords:  Atrial Fibrillation; CKD; Cardiovascular Diseases; Fibroblast Growth Factors; Humans; Hypertrophy, Left Ventricular; Inflammation; Leukocytes; Myocytes, Cardiac; Phosphates; Renal Insufficiency, Chronic; fibroblast growth factor 23; heart failure; hyperphosphatemia; phosphate binders; risk factors

Mesh：

Substances：

Year:  2017        PMID： 29074819      PMCID： PMC5718282          DOI： 10.2215/CJN.11011017

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  10 in total

Review 1.  Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis.

Authors:  Orlando M Gutiérrez
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-27       Impact factor: 8.237

Review 2.  Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.

Authors:  Julia J Scialla; Myles Wolf
Journal:  Nat Rev Nephrol       Date:  2014-04-01       Impact factor: 28.314

3.  Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study.

Authors:  Rupal Mehta; Xuan Cai; Alexander Hodakowski; Jungwha Lee; Mary Leonard; Ana Ricardo; Jing Chen; Lee Hamm; James Sondheimer; Mirela Dobre; Valentin David; Wei Yang; Alan Go; John W Kusek; Harold Feldman; Myles Wolf; Tamara Isakova
Journal:  Clin J Am Soc Nephrol       Date:  2017-08-07       Impact factor: 8.237

4.  Effects of phosphate binders in moderate CKD.

Authors:  Geoffrey A Block; David C Wheeler; Martha S Persky; Bryan Kestenbaum; Markus Ketteler; David M Spiegel; Matthew A Allison; John Asplin; Gerard Smits; Andrew N Hoofnagle; Laura Kooienga; Ravi Thadhani; Michael Mannstadt; Myles Wolf; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2012-07-19       Impact factor: 10.121

Review 5.  Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.

Authors:  Tamara Isakova; Joachim H Ix; Stuart M Sprague; Kalani L Raphael; Linda Fried; Jennifer J Gassman; Dominic Raj; Alfred K Cheung; John W Kusek; Michael F Flessner; Myles Wolf; Geoffrey A Block
Journal:  J Am Soc Nephrol       Date:  2015-05-12       Impact factor: 10.121

6.  Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.

Authors:  Tamara Isakova; Patricia Wahl; Gabriela S Vargas; Orlando M Gutiérrez; Julia Scialla; Huiliang Xie; Dina Appleby; Lisa Nessel; Keith Bellovich; Jing Chen; Lee Hamm; Crystal Gadegbeku; Edward Horwitz; Raymond R Townsend; Cheryl A M Anderson; James P Lash; Chi-Yuan Hsu; Mary B Leonard; Myles Wolf
Journal:  Kidney Int       Date:  2011-03-09       Impact factor: 10.612

7.  A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.

Authors:  Geoffrey A Block; Steven Fishbane; Mariano Rodriguez; Gerard Smits; Shay Shemesh; Pablo E Pergola; Myles Wolf; Glenn M Chertow
Journal:  Am J Kidney Dis       Date:  2014-11-04       Impact factor: 8.860

8.  Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice.

Authors:  Erica L Clinkenbeard; Emily G Farrow; Lelia J Summers; Taryn A Cass; Jessica L Roberts; Christine A Bayt; Tim Lahm; Marjorie Albrecht; Matthew R Allen; Munro Peacock; Kenneth E White
Journal:  J Bone Miner Res       Date:  2014-02       Impact factor: 6.741

9.  Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.

Authors:  Sophie Liabeuf; Jean-Philippe Ryckelynck; Najeh El Esper; Pablo Ureña; Christian Combe; Bertrand Dussol; Denis Fouque; Philippe Vanhille; Luc Frimat; Eric Thervet; Romuald Mentaverri; Dominique Prié; Gabriel Choukroun
Journal:  Clin J Am Soc Nephrol       Date:  2017-10-26       Impact factor: 8.237

10.  Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production.

Authors:  Valentin David; Aline Martin; Tamara Isakova; Christina Spaulding; Lixin Qi; Veronica Ramirez; Kimberly B Zumbrennen-Bullough; Chia Chi Sun; Herbert Y Lin; Jodie L Babitt; Myles Wolf
Journal:  Kidney Int       Date:  2016-01-04       Impact factor: 10.612
  10 in total
  1 in total

1.  Fibroblast Growth Factor 23 and Exercise Capacity in Heart Failure with Preserved Ejection Fraction.

Authors:  Jasleen Ghuman; Xuan Cai; Ravi B Patel; Sadiya S Khan; Jonathan Hecktman; Margaret M Redfield; Gregory Lewis; Sanjiv J Shah; Myles Wolf; Tamara Isakova; Rupal Mehta
Journal:  J Card Fail       Date:  2020-10-07       Impact factor: 5.712
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.